CKPT
Price:
$2.1
Market Cap:
$93.07M
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a tre...[Read more]
Industry
Biotechnology
IPO Date
2016-12-19
Stock Exchange
NASDAQ
Ticker
CKPT
According to Checkpoint Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.23. This represents a change of -25.76% compared to the average of -1.66 of the last 4 quarters.
The mean historical PE Ratio of Checkpoint Therapeutics, Inc. over the last ten years is -4.04. The current -1.23 PE Ratio has changed 2.94% with respect to the historical average. Over the past ten years (40 quarters), CKPT's PE Ratio was at its highest in in the December 2022 quarter at -0.52. The PE Ratio was at its lowest in in the June 2015 quarter at -21.79.
Average
-4.04
Median
-3.87
Minimum
-8.79
Maximum
-0.67
Discovering the peaks and valleys of Checkpoint Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 160.81%
Maximum Annual PE Ratio = -0.67
Minimum Annual Increase = -83.84%
Minimum Annual PE Ratio = -8.79
Year | PE Ratio | Change |
---|---|---|
2023 | -0.83 | 22.69% |
2022 | -0.67 | -83.84% |
2021 | -4.18 | -35.18% |
2020 | -6.44 | 160.81% |
2019 | -2.47 | 72.89% |
2018 | -1.43 | -63.08% |
2017 | -3.87 | -49.57% |
2016 | -7.67 | -12.72% |
The current PE Ratio of Checkpoint Therapeutics, Inc. (CKPT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.89
5-year avg
-2.92
10-year avg
-4.04
Checkpoint Therapeutics, Inc.’s PE Ratio is less than Mustang Bio, Inc. (-0.20), less than Reviva Pharmaceuticals Holdings, Inc. (-1.10), less than Fortress Biotech, Inc. (-0.71), less than Kodiak Sciences Inc. (-0.61), less than Fortress Biotech, Inc. (-0.71), less than Avenue Therapeutics, Inc. (-0.31), less than Pieris Pharmaceuticals, Inc. (-0.93), greater than Aileron Therapeutics, Inc. (-2.21), less than CytomX Therapeutics, Inc. (9.19), less than Instil Bio, Inc. (-0.78), less than Neoleukin Therapeutics, Inc. (-0.98), less than Spero Therapeutics, Inc. (4.06), greater than Assembly Biosciences, Inc. (-2.10), less than Achilles Therapeutics plc (-0.45), less than Cue Biopharma, Inc. (-0.63), less than Medicenna Therapeutics Corp. (-1.05), greater than XOMA Corporation (-17.42), greater than ZIVO Bioscience, Inc. (-2.46), less than Lumos Pharma, Inc. (-0.86),
Company | PE Ratio | Market cap |
---|---|---|
-0.20 | $10.22M | |
-1.10 | $44.68M | |
-0.71 | $44.00M | |
-0.61 | $121.54M | |
-0.71 | $40.38M | |
-0.31 | $4.05M | |
-0.93 | $22.50M | |
-2.21 | $60.66M | |
9.19 | $93.74M | |
-0.78 | $92.68M | |
-0.98 | $8.20M | |
4.06 | $71.07M | |
-2.10 | $107.81M | |
-0.45 | $29.58M | |
-0.63 | $28.70M | |
-1.05 | $0 | |
-17.42 | $332.97M | |
-2.46 | $37.03M | |
-0.86 | $30.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Checkpoint Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Checkpoint Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Checkpoint Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Checkpoint Therapeutics, Inc. (CKPT)?
What is the highest PE Ratio for Checkpoint Therapeutics, Inc. (CKPT)?
What is the 3-year average PE Ratio for Checkpoint Therapeutics, Inc. (CKPT)?
What is the 5-year average PE Ratio for Checkpoint Therapeutics, Inc. (CKPT)?
How does the current PE Ratio for Checkpoint Therapeutics, Inc. (CKPT) compare to its historical average?